Dabrafenib (GSK2118436, GSK2118436A)，又称达拉菲尼或达拉非尼，是特异性的BRAF V600E突变抑制剂，IC₅₀为0.7 nM，导致ERK磷酸化降低和抑制细胞增殖，具有抗癌活性，临床上常用于治疗BRAF V600E突变的转移性黑色素瘤，显著提高转移性黑色素瘤患者的存活率。

参考文献

[1] Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20.

[2] Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Aug 25;256:266-73.

[3] Meijles DN, et al. The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension. Clin Sci (Lond). 2021 Jul 30;135(14):1631-1647.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。